Avid Bioservices, Inc. reiterating revenue guidance for the fiscal year 2022. The company is reiterating revenue guidance for fiscal 2022 of $115 million to $117 million, a 20% to 22% increase over fiscal 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.995 USD | -0.21% | +2.28% | +7.15% |
04-30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
04-29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.15% | 445M | |
+2.97% | 94.74B | |
-3.68% | 37.28B | |
-11.70% | 32.68B | |
+74.21% | 27.72B | |
-13.85% | 16.19B | |
-2.56% | 13.88B | |
-12.21% | 11.58B | |
+188.83% | 10.92B | |
-53.94% | 9.54B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022